Table 1.
Baseline demographic and clinical characteristics by racial/ethnic group and cohort.
| Non-Hispanic Black participants in Sample 1 (NACC & ROS/MAP/MARS) | |||
|---|---|---|---|
| Variables | Total sample (n = 2,010) |
Women (n = 1,583, 78.8%) |
Men (n = 427, 21.2%) |
| Age in years, mean (SD) | 71.3 (7.59) | 71.4 (7.57) | 71.0 (7.67) |
| Education in years, mean (SD) | 14.9 (3.10) | 14.9 (3.02) | 14.9 (3.41) |
| APOE ε2 carriers, n (%) | 336 (16.7) | 263 (16.6) | 73 (17.1) |
| ε2/ε3, n (%) | 316 (15.7) | 248 (15.7) | 68 (15.9) |
| ε2/ε2, n (%) | 20 (1.00) | 15 (0.95) | 5 (1.17) |
| APOE ε4 carriers, n (%) | 662 (32.9) | 506 (32.0) | 156 (36.5) |
| ε3/ε4, n (%) | 595 (29.6) | 454 (28.7) | 141 (33.0) |
| ε4/ε4, n (%) | 67 (3.33) | 52 (3.28) | 15 (3.51) |
| APOE ε3/ε3 carriers, n (%) | 1,012 (50.3) | 814 (51.4) | 198 (46.4) |
| Total number of visits, median (SD) | 5 (3.96) | 6 (4.02)* | 5 (3.72)* |
| ε2 carriers, median (SD) | 6 (4.11) | 6 (4.20) | 6 (3.79) |
| ε4 carriers, median (SD) | 5 (3.70) | 5 (3.80) | 5 (3.33) |
| ε3/3 carriers, median (SD) | 6 (4.05) | 6 (4.07) | 5 (3.92) |
| Vascular risk score (range 0-1), mean (SD) | 0.36 (0.21) | 0.36 (0.21) | 0.36 (0.22) |
| Non-Hispanic White participants in Sample 1 (NACC & ROS/MAP) | |||
| Variables | Total sample (n = 9,766) |
Women (n = 6,344, 65.0%) |
Men (n = 3,422, 35.0%) |
| Age in years, mean (SD) | 73.0 (9.00) | 73.0 (9.14) | 72.9 (8.75) |
| Education in years, mean (SD) | 16.3 (2.83) | 16.0 (2.75)* | 16.9 (2.90)* |
| APOE ε2 carriers, n (%) | 1,260 (12.9) | 840 (13.2) | 420 (12.3) |
| ε2/ε3, n (%) | 1,211 (12.4) | 814 (12.8) | 397 (11.6) |
| ε2/ε2, n (%) | 49 (0.50) | 26 (0.41) | 23 (0.67) |
| APOE ε4 carriers, n (%) | 2,622 (26.8) | 1,670 (26.3) | 952 (27.8) |
| ε3/ε4, n (%) | 2,362 (24.2) | 1,508 (23.8) | 854 (25.0) |
| ε4/ε4, n (%) | 260 (2.66) | 162 (2.55) | 98 (2.86) |
| APOE ε3/ε3 carriers, n (%) | 5,884 (60.2) | 3,834 (60.4) | 2,050 (59.9) |
| Total number of visits, median (SD) | 6 (4.41) | 6 (4.48)* | 5 (4.27)* |
| ε2 carriers, median (SD) | 6 (4.53) | 6 (4.49) | 6 (4.61) |
| ε4 carriers, median (SD) | 5 (4.18) | 6 (4.26)* | 5 (4.02)* |
| ε3/3 carriers, median (SD) | 6 (4.48) | 6 (4.56)* | 5 (4.30)* |
| Vascular risk score (range 0-1), mean (SD) | 0.26 (0.21) | 0.25 (0.20)* | 0.28 (0.21)* |
| Non-Hispanic White participants in Sample 2 (ADNI & Prevent-AD) | |||
| Variables | Total sample (n = 915) |
Women (n = 542, 59.1%) |
Men (n = 373, 40.8%) |
| Age in years, mean (SD) | 70.1 (7.35) | 68.8 (7.17)* | 71.9 (7.24)* |
| Education in years, mean (SD) | 16.2 (2.92) | 15.7 (2.96)* | 16.9 (2.71)* |
| APOE ε2 carriers, n (%) | 108 (11.8) | 55 (10.1) | 53 (14.2) |
| ε2/ε3, n (%) | 107 (11.7) | 55 (10.1) | 52 (13.9) |
| ε2/ε2, n (%) | 1 (0.11) | 0 (0) | 1 (0.27) |
| APOE ε4 carriers, n (%) | 287 (31.4) | 176 (32.5) | 111 (29.8) |
| ε3/ε4, n (%) | 263 (28.7) | 160 (29.5) | 103 (27.6) |
| ε4/ε4, n (%) | 24 (2.62) | 16 (2.95) | 8 (2.14) |
| APOE ε3/ε3 carriers, n (%) | 520 (56.8) | 311 (57.3) | 209 (56.0) |
| Total number of visits, median (SD) | 5 (2.86) | 5 (2.70) | 5 (3.07) |
| ε2 carriers, median (SD) | 5 (2.61) | 5 (2.25) | 5 (2.96) |
| ε4 carriers, median (SD) | 5 (2.70) | 5 (2.60) | 5 (2.86) |
| ε3/3 carriers, median (SD) | 5 (2.99) | 5 (2.83) | 5 (3.21) |
| Vascular risk score (range 0-1), mean (SD) | 0.37 (0.19) | 0.37 (0.20) | 0.37 (0.18) |
*
p < .05. P-values represent results of independent samples t-tests and chi-square tests comparing men vs. women.
NACC: National Alzheimer’s Coordinating Center
ROS: Religious Orders Study
MAP: Memory Aging Project
MARS: Minority Aging Research Study
ADNI: Alzheimer’s Disease Neuroimaging Initiative
Prevent-AD: Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease
SD: standard deviation